in the absence of a submission from the holder of the marketing authorisation:
enfortumab vedotin (Padcev®) is not recommended for use within NHSScotland.
Indication under review: As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice613KB (PDF)
Medicine details
- Medicine name:
- enfortumab vedotin (Padcev)
- SMC ID:
- SMC2505
- Indication:
As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 July 2022